Abstract: The invention relates to a novel epitope of 180,000 daltons for the NCAM antigen and a monoclonal antibody, SEN7, directed against this antigen, and their use in diagnosis and therapy of small-cell carcinoma of the lung. The antibody SEN7 reacts significantly more selectively than previously known antibodies with cells of small-cell carcinoma of the lung, and binds with high avidity. In particular, no reaction occurs with leucocytes or healthy kidney or lung epithelial cells. The novel antigen is dominantly expressed by cells of small-cell carcinoma of the lung with a high copy number.
Type:
Grant
Filed:
March 16, 1995
Date of Patent:
March 25, 1997
Assignee:
Merck Patent Gesellschaft Mit Beschrankter Haftung
Abstract: Methods and compositions are provided for protecting antigens having a specific epitope associated with Melanoma. The epitope is present in melanoma cells but is essentially absent from melanocytes cites or other human tumor cells. The antibody can be used in diagnostic methods for histochemical detection of human melanoma of various progression stages and in treatment of melanoma.
Abstract: Hybridoma 4A11 produces a murine IgM monoclonal antibody specifically against endothelial cells in diseased tissues such as rheumatoid and osteoarthritis synovial tissues, and psoriatic skin. The 4A11 antibody has possible clinical utility for detection of human endothelial cells mainly in inflamed and malignant disease states.
Abstract: A new cell line TriH8 is obtained by fusing a particular sub-clone, A431c, of the human epidermoid carcinoma cell line A431 with the TOS/H8 (human/human) hybridoma. Fused cell TriH8 has been deposited under FRI accession number FERM BP-4452. The fused cell is capable of proliferating in basal medium without addition of serum or growth factor. The cell line is more effective in producing antibody (IgM) than the donor cell TOS/H8.